Medicamen Biotech Ltd
Medicamen Biotech Ltd
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations.
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations.
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.